India Pesticides Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/wo2gpoodz50rn09f46pdbnq7.pdf

Key Takeaways


Demand & Pricing Environment

D. K. Jain: "Export side demand is also picking up madam now. There has been -- in the last years, the oversupply was there from Chinese manufacturer, but now slowly it is getting reduced and the demand is increasing. And with this American tariff situation, we are slightly positively poised for U.S. markets."

Revenue Growth Levers


Margins & Profitability

D. K. Jain: "Sir, we -- it will be our effort and continuous effort what we are making to increase the total overall market margin levels to the earlier one about 25%. And we feel that we should be able to do that in few years of time by backward integrating the products, by optimizing the operating conditions, then by selecting products with slightly higher margin levels."

Working Capital & Cash Flow


Strategic Initiatives & Competitive Position

Anand Swarup Agarwal: "Our strategic initiative of backward integration positions us comparatively against global manufacturers, particularly those from China, in several key products."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue targetINR 1,000 croreFY26
EBITDA margin18% to 20%FY26
Revenue growth CAGR15% to 20%Next 2–3 years
Capex outlayINR 116 crore (IPL + Shalvis)FY26
Cumulative capexOver INR 200 crore across existing facility and ShalvisOver 2 years
Pretilachlor capacity8,500 tons installedBy August
Pretilachlor growth20% compoundedNext 2–3 years
Formulations growth20% maintainedFY26
Key molecule demand growth (Captan, Prosulfocarb, Folpet)10% to 15%FY26
H1 revenue split~55% of full-year revenueFY26
Working capital daysNormalize to ~220 days, then reduce by 10–15 daysComing quarters
Long-term EBITDA marginReturn to ~25%"Few years"
Debt positionRemain debt-free, fund all expansion from internal accrualsOngoing

Key Metrics

MetricQ4 FY25
Revenue₹211 cr, total revenue for the quarter
FY25 revenue₹844 cr, +21% YoY
EBITDA₹35 cr, +373% vs same quarter last year
EBITDA margin16%, margin expansion due to price stability and higher operating leverage
Net profit₹22 cr, PAT margin 10%, expanded by 950 bps YoY
FY25 net profit₹82 cr, +37% YoY, PAT margin 9.7%
FY26 revenue guidance₹1,000 cr, projected for next fiscal year
FY26 EBITDA margin guidance18% to 20%, improvement from current 16%
Revenue growth outlook15% to 20% CAGR in near next 2 to 3 years
Export revenue (Q4)₹88 cr, vs ₹38 cr in same period last year
FY25 export revenue₹315 cr, vs ₹269 cr in FY24
FY25 domestic revenue₹513 cr, vs ₹410 cr in FY24
Technical segment capacity utilization~62%, increased from ~41%, up approximately 50%
Formulation capacity utilizationupward of 95%, prompting plans for expansion
FY26 planned capex₹116 cr, for India Pesticides and Shalvis Specialities
Working capital days~250 days last quarter, normalized going forward ~220 days
Pretilachlor revenuein excess of ₹100 cr this molecule, vs ₹70 cr last year
Pretilachlor capacity expansion valuemore than ₹300 cr at 8,500 tons capacity
Bulk formulation exports~₹50 cr in FY25, up from ₹10-12 cr in FY24
Formulations business growthmore than 20% compounded
Operating cash flow from operations (FY25)₹2 cr, reduced due to higher debtor days and inventory
Registrations received in FY254 technical, 19 formulations from CIB India; 4 in EU/UK, 2 in USA, 2 formulations in Australia